首页 > 市场调查报告书 > 医疗设备

医学影像诊断癌症个人化医学分子呈像/呈影剂核子医学

放射性药物治疗诊断学市场规模、份额及成长分析（按类型、来源、应用、最终用户和地区划分）－2026-2033年产业预测

市场调查报告书

商品编码

1919879

放射性药物治疗诊断学市场规模、份额及成长分析（按类型、来源、应用、最终用户和地区划分）－2026-2033年产业预测

Radiopharmaceutical Theranostics Market Size, Share, and Growth Analysis, By Type, By Source, By Application, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2026年01月06日 | 出版商:

SkyQuest | 英文 187 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，全球放射性药物治疗诊断学市场规模将达到 23 亿美元，到 2025 年将达到 25.7 亿美元，到 2033 年将达到 62.3 亿美元，在预测期（2026-2033 年）内，复合年增长率为 11.7%。

随着癌症和神经系统疾病发病率的不断上升，标靶治疗的需求日益迫切，全球放射性药物治疗诊断学市场正蓬勃发展。这种创新方法整合了诊断和治疗功能，透过提高效率和改善治疗效果来提升患者照护。精准医疗的日益普及、核医领域投资的不断增长以及影像技术的进步，正推动着该技术在医院和研究机构的广泛应用。在监管机构的支持以及与製药和生物技术公司的合作推动下，该领域的未来前景十分光明，这些合作旨在促进创新并拓展全球市场。然而，高昂的研发成本、严格的法规结构、有限的同位素供应、安全隐患以及基础设施不足等挑战，可能会阻碍该技术在某些地区的广泛应用。

全球放射性药物治疗诊断学市场驱动因素

全球放射性药物治疗诊断学市场的发展动力源自于放射性药物独特的标靶治疗能力，即能够同时诊断和治疗疾病。这种双重功能使临床医生能够最大限度地减少对健康组织的辐射暴露，从而改善患者预后并缩短復原时间。治疗诊断学疗法在现代医学中日益重要，能够有效应对复杂的疾病状态，尤其是在癌症和某些神经退化性疾病领域。标靶治疗的整合不仅简化了治疗流程，还提供了更个人化的患者照护方案，显着促进了市场成长。

全球放射性药物治疗诊断学市场面临的限制因素

全球放射性药物治疗诊断学市场面临的主要限制因素是医用同位素供应有限，尤其是在缺乏本地生产设施的地区。这种短缺，加上运输和储存方面的挑战，阻碍了患者及时获得治疗。此外，严格的法规结构增加了对集中供应商的依赖，使分销流程更加复杂。因此，医疗机构可能难以确保治疗诊断学解决方案的稳定及时供应，最终影响患者的治疗效果和市场的整体成长潜力。应对这些挑战对于提高治疗诊断学应用的可近性和效率至关重要。

全球放射性药物治疗诊断学市场趋势

全球放射性药物治疗诊断学市场正经历着一场变革性趋势：个人化治疗诊断学方法的兴起。这项创新反映了精准医疗的广泛发展趋势，它能够开发出针对个别患者特征设计的放射性药物，从而实现诊断和治疗的同步进行。透过提高标靶治疗的疗效并最大限度地减少副作用，这种个人化模式显着改善了患者的治疗效果，并提升了患者的整体体验，尤其是在肿瘤学和神经病学领域。随着医疗保健产业不断重视个人化医疗，对这些先进治疗诊断学解决方案的需求预计将大幅成长，从而推动市场成长并支持持续的研发投入。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Novartis AG
Bayer AG
Eli Lilly and Company
Bristol Myers Squibb
AstraZeneca
Telix Pharmaceuticals
Lantheus Holdings, Inc.
ITM Isotope Technologies Munich SE
GE HealthCare
Siemens Healthineers
Curium Pharma
Radiopharm Theranostics
Jubilant Pharmova
Eckert & Ziegler
Clarity Pharmaceuticals
Actinium Pharmaceuticals
Ariceum Therapeutics
RadioMedix, Inc.
NorthStar Medical Radioisotopes
Aktis Oncology

结论与建议

简介目录

Product Code: SQMIG35I2494

Global Radiopharmaceutical Theranostics Market size was valued at USD 2.3 billion in 2024 and is poised to grow from USD 2.57 billion in 2025 to USD 6.23 billion by 2033, growing at a CAGR of 11.7% during the forecast period (2026-2033).

The global radiopharmaceutical theranostics market is experiencing significant momentum driven by the increasing prevalence of cancers and neurological conditions, highlighting the need for targeted therapies. This innovative approach integrates diagnostic and therapeutic capabilities, enhancing patient care through improved efficiency and outcomes. Growing emphasis on precision medicine, coupled with heightened investments in nuclear medicine and advancements in imaging technologies, is fostering broader acceptance and implementation in hospitals and research institutions. This sector's future appears promising, buoyed by regulatory support and collaborations with pharmaceutical and biotechnology firms that aim to drive innovation and facilitate global market entry. However, challenges such as substantial development costs, stringent regulatory frameworks, limited isotope availability, safety concerns, and a lack of infrastructure may impede widespread adoption in certain regions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Radiopharmaceutical Theranostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Radiopharmaceutical Theranostics Market Segments Analysis

Global Radiopharmaceutical Theranostics Market is segmented by Type, Source, Application, End User and region. Based on Type, the market is segmented into Companion Diagnostic Radiopharmaceuticals and Targeted Therapeutic Radiopharmaceuticals. Based on Source, the market is segmented into Nuclear Reactors and Cyclotrons. Based on Application, the market is segmented into Oncology, Cardiology, Neurology and Other Applications. Based on End User, the market is segmented into Hospitals, Diagnostic Imaging Centers, Research Institutes and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Radiopharmaceutical Theranostics Market

The global radiopharmaceutical theranostics market is driven by the unique capability of radiopharmaceuticals to simultaneously diagnose and treat diseases through one targeted approach. This dual functionality allows clinicians to minimize exposure to healthy tissues, leading to enhanced patient outcomes and shorter recovery periods. By effectively addressing intricate disease conditions, particularly in the realm of cancer and specific neurodegenerative disorders, theranostic therapies are becoming increasingly vital in modern medicine. The integration of targeted therapies not only streamlines the treatment process but also provides a more personalized approach to patient care, thereby significantly contributing to the market's growth.

Restraints in the Global Radiopharmaceutical Theranostics Market

A significant limitation in the Global Radiopharmaceutical Theranostics market is the restricted availability of medical isotopes, especially in regions lacking local production facilities. This scarcity, coupled with challenges related to transportation and storage, hinders timely access to treatments for patients. Furthermore, stringent regulatory frameworks intensify the dependence on centralized suppliers, thereby complicating the distribution process. As a result, healthcare providers may struggle to ensure consistent and timely delivery of theranostic solutions, which could ultimately affect patient outcomes and the overall growth potential of the market. Addressing these issues is crucial for enhancing accessibility and efficiency in theranostic applications.

Market Trends of the Global Radiopharmaceutical Theranostics Market

The Global Radiopharmaceutical Theranostics market is witnessing a transformative trend characterized by the rise of tailored theranostic approaches. This innovation reflects the broader movement towards personalized medicine, enabling the development of radiopharmaceutical agents designed to cater to individual patient profiles for simultaneous diagnosis and treatment. By enhancing targeted therapeutic efficacy while minimizing adverse effects, this personalized model significantly improves patient outcomes and elevates the overall patient experience, particularly in oncology and neurology. As healthcare continues to prioritize individualized care, the demand for these advanced theranostic solutions is expected to surge, driving market growth and fostering ongoing research and development.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index, 2025
PESTEL Analysis
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Technology Assessment

Global Radiopharmaceutical Theranostics Market Size by Type & CAGR (2026-2033)

Market Overview
Companion Diagnostic Radiopharmaceuticals
Targeted Therapeutic Radiopharmaceuticals

Global Radiopharmaceutical Theranostics Market Size by Source & CAGR (2026-2033)

Market Overview
Nuclear Reactors
Cyclotrons

Global Radiopharmaceutical Theranostics Market Size by Application & CAGR (2026-2033)

Market Overview
Oncology
Cardiology
Neurology
Other Applications

Global Radiopharmaceutical Theranostics Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Diagnostic Imaging Centers
Research Institutes
Other End Users

Global Radiopharmaceutical Theranostics Market Size & CAGR (2026-2033)

North America (Type, Source, Application, End User)
- US
- Canada
Europe (Type, Source, Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Source, Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Source, Application, End User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Source, Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Telix Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lantheus Holdings, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ITM Isotope Technologies Munich SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE HealthCare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Curium Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Radiopharm Theranostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jubilant Pharmova
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eckert & Ziegler
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Clarity Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Actinium Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ariceum Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
RadioMedix, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NorthStar Medical Radioisotopes
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aktis Oncology
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments